Rite Aid names CIO
CAMP HILL, Pa. — Rite Aid has appointed Matt Lynch, an information technology executive with nearly 30 years of experience, as SVP and CIO.
Lynch succeeds Don Davis, who is retiring from the company after 14 years of service.
In this position, Lynch will be responsible for all aspects of the company’s technology and information operations, including computer systems, network infrastructure, telecommunications and data security, as well as the continued development and execution of Rite Aid’s immediate and long-term information technology strategy. Lynch will report to Frank Vitrano, Rite Aid’s senior EVP, CFO and chief administrative officer.
“Matt is a seasoned information technology professional with diverse business systems’ management and deep retail experience,” Vitrano said. “Additionally, his expertise with advanced systems — spanning all key business functions — will be extremely beneficial to Rite Aid as we continue to enhance our information technology and services platforms to help us achieve our dual goals of delivering a superior customer experience and driving continued growth for our company.”
Most recently, Lynch served as SVP and CIO for Dick’s Sporting Goods, a sporting goods retailer, overseeing the enterprise IT function for all brands and e-commerce businesses. Prior to joining Dick’s Sporting Goods, Lynch held various executive information technology positions at ShopKo.
Teva’s Synribo approved for home administration
JERUSALEM — Teva Pharmaceutical Industries on Monday announced that the Food and Drug Administration approved Synribo (omacetaxine mepesuccinate) for injection, to include home administration. With the announcement of the approval, physicians who treat adults with chronic or accelerated phase CML (who are no longer responding to or can’t tolerate two or more tyrosine kinase inhibitors) now have the option to allow patients to administer Synribo at home.
“As we continue to expand our oncology portfolio and services at Teva, the updated labeling for Synribo demonstrates our commitment to improving the overall experience and lowering barriers to treatment for people living with CML,” said Bill Campbell, VP and general manager, Teva Oncology. “Home administration can reduce the number of required doctor office visits for patients being treated with Synribo, while still maintaining close collaboration with their healthcare provider to manage their treatment regimen.”
Teva is finalizing a comprehensive specialty pharmacy support program, which will help facilitate home administration of Synribo for HCPs, their patients and caregivers. It’s expected to "go live" in the second quarter of 2014.
“As an oncology nurse practitioner who has treated CML patients for nearly 20 years, I’m thrilled to see this unique therapy become available for home administration,” said Sandra Corbin, CRNP at Calvert Hematology and Oncology. “Patients may initially express concern at the thought of self-injecting — but with training and support, most can become skilled at administering the subcutaneous injections.”
Walgreens posts 8.8% boost in April sales
DEERFIELD, Ill. — Walgreens posted April sales of $6.49 billion, an increase of 8.8% from $5.96 billion for the same month in fiscal 2013.
Total front-end sales increased 8.8% in April compared with the same month in fiscal 2013, while same-store front-end sales increased 8.2%. Customer traffic in comparable stores increased 2.6% while basket size increased 5.6%.
For the combined March/April period that includes the Easter holiday season impact, comparable store front-end sales increased by 2.1%, while customer traffic in comparable stores decreased 0.9% and basket size increased 3%.
Prescriptions filled at comparable stores increased by 3.5% in April and increased 4.3% on a calendar day-shift adjusted basis. April 2014 had one additional Wednesday and one fewer Monday compared with April 2013. The retailer noted that the calendar shifts negatively impacted prescriptions filled at comparable stores by 0.8 percentage point.
April pharmacy sales increased by 9.2%. Comparable store pharmacy sales increased 7.3% and increased by a calendar day-shift adjusted 8.1%. Calendar day shifts negatively impacted pharmacy sales in comparable stores by 0.8 percentage point. Calendar day-shift adjusted comparable store pharmacy sales were negatively impacted by 1.3 percentage points due to generic drug introductions in the last 12 months. Pharmacy sales accounted for 64.5% of total sales for the month, the company stated.
Sales in comparable stores increased by 7.6% in April. Calendar day shifts negatively impacted total comparable sales by 0.5 percentage point. Generic drug introductions in the last 12 months negatively impacted total comparable sales by 0.8 percentage point.
Sales for the combined months of March and April 2014 increased 6.6% from the same two months in 2013. Comparable store sales for the March/April period increased 5.5%.